Alison Lawton, president and chief operating officer of Kaleido Biosciences, has been appointed CEO of the microbiome therapies developer. Lawton succeeds Michael Bonney, who will now serve as executive chairman of Kaleido’s board of directors. Bedford, MA-based Kaleido also promoted CFO Joshua Brumm to COO. The company says Brumm will continue to oversee finance in his new role. Kaleido emerged last year from venture capital firm Flagship Pioneering, which incubated the startup for two years.